Clinical Factors in Relapses of Wilms’ Tumor – Results for the Polish Pediatric Solid Tumors Study Group

Abstract

Of these 34 patients, 11 initially had CS I, seven were at CS II, four were at CS III, 11 were at CS IV and one had CS V. There were eight patients with second recurrences; of these, seven were in the INT risk group and one in the high histological risk group. There was no correlation between age (p = 0.256) or gender (p = 0.538) and the risk of tumor recurrence. In the study group, seven out of 10 patients with local recurrences are alive; as are 13 out of 22 patients with distant recurrences

Comprehensive Analysis of a Long Noncoding RNA-Associated Competing Endogenous RNA Network in Wilms Tumor

“…2 The overall 5-year survival rate for WT in the United States is 92%, whereas the proportion plummets to just 78% in poor parts of the world with fewer medical resources. 3 Although a great improvement in survival rate has been achieved over past few decades through combination therapy including surgery, radiotherapy, and chemotherapy, 4 the prognoses of patients with WT with higher risks of treatment failure or a more advanced stage are still poor. In addition, the exposure to toxic therapies has potential side effects, 5 such as occurrence of renal dysfunction, 6 cardiotoxicity, 6 musculoskeletal problems, 7 and development of secondary malignant neoplasms.…”